Anzeige
Mehr »
Dienstag, 22.07.2025 - Börsentäglich über 12.000 News
100% seit April - und trotzdem erst der Anfang? Kupfer wird zum Turbo-Rohstoff des Jahres!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H8SU | ISIN: FR0013296746 | Ticker-Symbol: 3MM
Frankfurt
21.07.25 | 15:29
1,196 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ADVICENNE Chart 1 Jahr
5-Tage-Chart
ADVICENNE 5-Tage-Chart
RealtimeGeldBriefZeit
1,2001,22009:28

Aktuelle News zur ADVICENNE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAdvicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility470Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now...
► Artikel lesen
02.07.XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025143Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital...
► Artikel lesen
30.06.Advicenne Confirms the Upcoming Filing for Registration of ADV7103 in the USA and is Securing Its Financing Through Loan Restructuring and the Launch of a Rights Issue.274Submission of the US marketing authorization application for ADV7103 planned in Q4 2025, following positive feedback from the FDA on the additional data submitted. Repayment of tranches...
► Artikel lesen
29.04.ADVICENNE: Advicenne met à disposition son Document d'Enregistrement Universel 20242
29.04.Advicenne 2024 Universal Registration Document Made Available229Regulatory News: Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering...
► Artikel lesen
27.03.Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States451Total product sales of Advicenne up 9.4% to €4.9m Operating cash consumption below €1M by 2025 and significant improvement in cash flow Cash position of €3.2 million on December...
► Artikel lesen
29.01.Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria411Regulatory News: Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering...
► Artikel lesen
ADVICENNE Aktie jetzt für 0€ handeln
23.01.Advicenne Announces 2024 Gross Sales14092024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024...
► Artikel lesen
19.12.24Advicenne Finalizes Agreement with Primex Pharmaceuticals AG465Regulatory News: Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering...
► Artikel lesen
28.11.24Advicenne Announces its 2025 Financial Calendar168Regulatory News: Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering...
► Artikel lesen
01.10.24Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103426FDA agrees to submission of a marketing authorization application for ADV7103 in dRTA without further clinical studies. The positive orphan drug designation decision for ADV7103 in cystinuria...
► Artikel lesen
18.09.24Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities448Sibnayal® gross sales up 28% to €1.25 million including royalties paid by commercial partners (16% excluding royalties) Continued progress towards current operating breakeven Cash...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1